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The acute chest syndrome is the lead-
ing cause of death among patients with sickle cell
disease. Since its cause is largely unknown, therapy
is supportive. Pilot studies with improved diagnostic
techniques suggest that infection and fat embolism




In a 30-center study, we analyzed 671 ep-
isodes of the acute chest syndrome in 538 patients
with sickle cell disease to determine the cause, out-
come, and response to therapy. We evaluated a treat-
ment protocol that included matched transfusions,
bronchodilators, and bronchoscopy. Samples of blood
and respiratory tract secretions were sent to central
laboratories for antibody testing, culture, DNA test-




Nearly half the patients were initially ad-
mitted for another reason, mainly pain. When the
acute chest syndrome was diagnosed, patients had
hypoxia, decreasing hemoglobin values, and progres-
sive multilobar pneumonia. The mean length of hos-
pitalization was 10.5 days. Thirteen percent of pa-
tients required mechanical ventilation, and 3 percent
died. Patients who were 20 or more years of age had
a more severe course than those who were younger.
Neurologic events occurred in 11 percent of patients,
among whom 46 percent had respiratory failure.
Treatment with phenotypically matched transfusions
improved oxygenation, with a 1 percent rate of al-
loimmunization. One fifth of the patients who were
treated with bronchodilators had clinical improve-
ment. Eighty-one percent of patients who required
mechanical ventilation recovered. A specific cause of
the acute chest syndrome was identified in 38 per-
cent of all episodes and 70 percent of episodes with
complete data. Among the specific causes were pul-
monary fat embolism and 27 different infectious
pathogens. Eighteen patients died, and the most com-
mon causes of death were pulmonary emboli and in-
fectious bronchopneumonia. Infection was a con-




Among patients with sickle cell dis-
ease, the acute chest syndrome is commonly precip-
itated by fat embolism and infection, especially com-
munity-acquired pneumonia. Among older patients
and those with neurologic symptoms, the syndrome
often progresses to respiratory failure. Treatment with
transfusions and bronchodilators improves oxygen-
ation, and with aggressive treatment, most patients
who have respiratory failure recover. (N Engl J Med
2000;342:1855-65.)
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HE acute chest syndrome is the leading
cause of death and hospitalization among





mal treatment has not been established
because the cause remains largely unknown. Both
infectious and noninfectious causes have been de-





 Pulmonary fat embolism has been iden-
tified during autopsies and in studies examining fat-





 However, the number of patients included
in these reports is too small for general recommen-




Appropriate therapy remains controversial. The an-
tibiotics used are based on organisms identified dec-
ades ago, and data regarding the use of new antibi-
otics for emerging pathogens are limited. Antiviral
treatments have not been carefully studied in patients
with sickle cell disease. Furthermore, the benefit of
transfusion and bronchodilator therapy has not been
clearly established.
In 1993, we initiated a prospective, multicenter
study of the acute chest syndrome in order to deter-
mine the causes, incidence, and clinical outcome of






Patients were enrolled at 30 centers. Each institution had a
principal investigator, data coordinator, pulmonologist, and nurse
assigned to the study. Patients were enrolled after they or their
parents or guardians provided written informed consent. The in-
T
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stitutional review board at each participating center approved the
study. To be eligible, patients had to have a phenotype of hemo-





electrophoretic analysis of the hemoglobin chains and to have had
an episode of the acute chest syndrome. The acute chest syndrome
was defined on the basis of the finding of a new pulmonary infil-
trate involving at least one complete lung segment that was con-
sistent with the presence of alveolar consolidation, but excluding
atelectasis. In addition, the patients had to have chest pain, a tem-
perature of more than 38.5°C, tachypnea, wheezing, or cough.
From March 1993 through March 1997, 721 episodes of the
acute chest syndrome were reported. Fifty episodes were excluded:
30 because of missing forms, and 20 because of diagnostic error
and withdrawal from the study. Data were available on 671 episodes
in 538 patients, including 443 patients with a single episode and
95 with recurrent episodes (69 with two episodes, 16 with three
episodes, 8 with four episodes, and 2 with five episodes).
 
Treatment Protocol and Data Collection
 
A standardized treatment and monitoring protocol was used
(Fig. 1). Transfusion guidelines included the use of units that
were depleted of leukocytes, negative for sickle cells, and matched
with respect to Rh C and E antigens and Kell antigens. Patients
were monitored for alloantibodies by standard tests at enrollment,
before and after each transfusion, and at follow-up. Patients re-
ceived transfusions to improve respiratory status at the discretion
of their physicians. Standardized forms were used to document
medical history, findings on daily physical examinations, findings
on radiography, oxygenation status, the need for transfusions, com-
plications of bronchoscopy, and findings on follow-up.
 
Laboratory Studies and Diagnostic Criteria
 
Blood for culture was obtained before therapy whenever pos-
sible. Bronchoscopy was performed to obtain samples for aerobic
and anaerobic cultures and for the fat embolism assay. In patients
who did not undergo bronchoscopy, sputum was collected either




A bacterial cause of the acute chest syndrome was identified on the
basis of a positive blood culture or heavy growth of an organism in
a bronchial culture with confirmatory results on Gram’s staining.





 and cultures for mycoplasma were performed with




 All viral and mycoplasma isolates





 serogroups 1 through 6 were de-
tected by indirect immunofluorescence staining.
Serum samples were collected during the acute phase of illness
and during convalescence; the median interval between sample col-
lection was 48 days. An increase in antibody titers by a factor of at
















confirmed by specific IgM antibody tests.
In a subgroup of patients, pairs of serologic samples and bron-
choscopic or sputum samples were sent to the laboratory of Dr.
Julias Schachter (University of California, San Francisco) for cul-
ture for chlamydia and for measurement of chlamydia antibody















was based on an increase in IgG antibody titers by a factor of 4 in





munofluorescence analysis, an initial IgM antibody titer of more
than 1:16, or a positive polymerase-chain-reaction assay.
Intracellular lipid from alveolar macrophages obtained from
bronchial samples was evaluated for evidence of pulmonary fat em-
bolism according to a modification of the Corwin index, a method





 Samples obtained at autopsy and histopathologi-
cal slides were analyzed by the central pathology unit for evidence




We performed inferential statistical analyses after eliminating all
but the first episode of the acute chest syndrome for each patient.
For comparisons of clinical data among age groups, we compared
proportions using chi-square analysis with Yates’ correction or Fish-
er’s exact test. All confidence intervals were two-sided, and a P val-
ue of 0.05 or less was considered to indicate statistical significance.
For comparison of means, we used Student’s t-test or analysis of
variance; results are reported as means ±SD. When assumptions
for parametric analyses were not met, the Wilcoxon rank-sum test
was used. When summarizing data concerning causation, we in-
cluded all episodes.
We developed a Cox proportional-hazards regression model for
the duration of hospitalization in which we reduced age and 40 oth-
er variables from the patients’ medical history and hospital course
to 19 covariates that were significant on univariate analyses. These
variables were included in a multivariable proportional-hazards re-
gression model designed to identify factors that were independ-
ently associated with the time of discharge from the hospital. Data
on patients were censored at the time of death, and one variable for
which more than 20 percent of values were missing was not en-
tered into the model.
Multivariable logistic-regression models were developed for the
presence or absence of respiratory failure and neurologic compli-
cations in order to identify predictors of these events at the time
of diagnosis. We performed univariate logistic-regression analyses
of these outcomes and 35 clinical variables of interest. Only clinical
variables that were significantly related in the univariate analyses





Diagnosis and Symptoms of the Acute Chest Syndrome 
at Admission
 
The characteristics of the patients are summarized
in Table 1. Data on one patient (one episode) were
excluded because the patient’s birth date was not
known. Nearly half the patients were admitted with
a diagnosis other than the acute chest syndrome; 72
percent of these patients were admitted because of a
vaso-occlusive crisis. Among patients who were not
admitted for the acute chest syndrome, radiographic
and clinical findings of the syndrome appeared a mean
of 2.5 days after admission. The symptoms at pres-
entation varied with age (Table 1).
 
Hospital Course and Treatment
 
The findings on physical and radiographic exami-
nation are summarized in Table 2. During hospitaliza-
tion, multilobar involvement, especially of the lower
lobes, was common in all age groups, and effusion was
present in 55 percent of all patients. All patients were
treated with antibiotics and, on average, became afe-
brile after a mean of two days of hospitalization.
At diagnosis, the mean oxygen saturation was 92
percent while the patients were breathing room air.
There was no significant difference in the extent of
hypoxia among the age groups, but younger patients
were less likely to be treated with oxygen and me-
chanical ventilation. Thirteen percent of all patients
required mechanical ventilation, and the mean dura-
tion of mechanical ventilation was 4.6 days. Eighty-
one percent of the patients who required mechanical
ventilation recovered.
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 Protocol for Treatment and Monitoring.
PCR denotes polymerase chain reaction. The numbers in parentheses are the numbers of episodes.
Nasopharyngeal sampleE
(n=499)
Viral culture (n=581) and test forE
Legionella pneumophila (n=582)E











Serum samples obtained duringE










Oxygen therapy required for patients with a partial pressure of arterial oxygen of less than 60 mm HgE
or oxygen saturation of less than 90 percent.E
Antibiotic therapy, consisting of cephalosporin and erythromycin intravenously until fever had been absentE
for at least 24 hours and then orally, for a total of 7 to 10 days, given to all patients.E
Fluid management individualized on the basis of cardiopulmonary status. 1 to 11⁄2 times daily fluid require-E
ments (intravenous plus oral), with modifications based on daily weight and intake and output analysis.E
Respiratory therapy consisting of incentive-spirometry protocol for all patients who were able to perform it.E
Pain-management protocol included guidelines for patient-controlled analgesia and dosages of narcoticsE
and nonsteroidal agents, with the goal being to prevent respiratory splinting and avoid hypoventilation andE
narcosis; cardiorespiratory monitoring was continuous.E
Bronchodilator therapy given to patients with evidence of reactive airway disease.E
Transfusion therapy given to patients for clinical distress, at physician’s discretion.
Laboratory Monitoring
Daily blood count, serial chemistry panels.E
Pretransfusion and post-transfusion studies, including concentrations of hemoglobin S and partial pressureE
of oxygen.E
Continuous (or every 8 hours) pulse oximetry.E
Daily arterial-blood gas measurements until partial pressure of arterial oxygen was 75 mm Hg or greaterE
while patient was breathing room air.E
Daily chest radiography until improvement was documented.E
Pulmonary-function tests at onset of episode, at discharge, and at the 6-week follow-up visit in patientsE
who were able to participate.
Enrollment of 538 patients with 671 episodes of acute chest syndrome
Diagnostic Tests
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The mean forced expiratory volume in one second
during the acute phase of the syndrome was 53 per-
cent of the predicted value. Sixty-one percent of
patients were treated with bronchodilators, and 20
percent of these patients had clinical improvement
(defined as an increase of 15 percent in forced expir-
atory volume in one second, expressed as a percent-
age of the predicted value). Among those with im-
provement, the mean forced expiratory volume in
one second was initially 41 percent of the predicted
value and increased to 52 percent, a 27 percent im-
provement.
Seventy-two percent of patients received transfu-
sions (Table 2). The mean number of transfusions
per patient was 1.6, and the mean number of units
per patient was 3.2. Sixty-eight percent of patients
 
*Because of rounding, percentages may not total 100. Data on one patient were excluded because
the patient’s birth date was not known.
†P values were calculated by chi-square analyses.
‡Other reasons included a vaso-occlusive event, anemia, fever, infection, gastrointestinal or abdom-




































































































































Mean age at first episode of acute chest
syndrome (yr)










Aseptic necrosis or fracture
Asthma
Smoking



























































































































Pain in arms and legs
Abdominal pain
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*Data on one patient were excluded because the patient’s birth date was not known.
†P values were calculated by chi-square analyses.
‡The partial pressure of arterial oxygen was measured while the patient was breathing room air.
§Oxygen saturation was measured by pulse oximetry while the patient was breathing room air.
¶This category included any painful episode that occurred during hospitalization.
¿This category included respiratory failure, pneumothorax, and empyema requiring thoracentesis.
**This category included arrhythmia, congestive heart failure, hypertension, and hypotension.
††This category included gastrointestinal hemorrhage, ileus, and bowel infarction.
‡‡This category included all days of hospitalization, even those that occurred before the diagnosis




























































































































Findings on physical examination
Respiratory rate >30/min (%)
Mean peak respiratory rate/min




Mean no. of lobes involved at 
diagnosis











































Mean decrease in hemoglobin 
from steady-state value (g/dl)





Mean partial pressure of arterial 
oxygen at diagnosis (mm Hg)‡





















































































































































Mean duration of hospitalization 
(days)‡‡
10.5 9.7 10.0 12.8 0.04
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received simple transfusions, and 64 percent received
phenotypically matched red cells. Oxygenation sig-
nificantly improved with transfusion. On average, the
partial pressure of arterial oxygen while the patients
were breathing room air was 63 mm Hg before trans-
fusion and 71 mm Hg after transfusion (P<0.001).
Similarly, oxygen saturation increased from 91 per-
cent to 94 percent with transfusion (P<0.001). When
we analyzed only patients who had hypoxia before
transfusion (defined as an oxygen saturation of less
than 91 percent), the values increased from 86 per-
cent to 93 percent (P<0.001). Both simple and ex-
change transfusion resulted in similar improvements
in oxygenation. Overall, 2.4 percent of patients had
a new red-cell antibody, including 1 percent of the
patients who received phenotypically matched units
and 5 percent of those who received standard trans-
fusions (P=0.02).
The mean hospital stay was 10.5 days. Cox pro-
portional-hazards regression analysis of 19 covariates
that were significant on univariate analysis showed
that after adjustment for the remaining factors, an
age of 20 years or more, a history of vaso-occlusive
events, a platelet count of 0 to 199,000 per cubic
millimeter at diagnosis, pain in the arms and legs at
presentation, extensive radiographic abnormalities, ev-
idence of effusion on radiographic analysis, fever, treat-
ment by transfusion, and respiratory failure were in-





Older patients (particularly those who were 20
years of age or older) were more likely to have com-
plications and to die during hospitalization (Table 2).
Respiratory failure was documented in 13 percent of
patients. To identify predictors of respiratory failure
that were present at the time of diagnosis, we devel-
oped a multivariable logistic-regression model that in-
cluded age and 10 variables that were significant on
univariate analyses. Radiographic evidence of extensive
lobar involvement, a platelet count of 0 to 199,000
per cubic millimeter at diagnosis, and a history of car-
diac disease remained independent predictors of res-
piratory failure (Table 3).
Neurologic events occurred in 11 percent of pa-
tients. The most common were altered mental status
(in 56 percent), seizures (11 percent), and neuromus-
cular abnormalities (8 percent). Anoxic brain injury
occurred in three patients, central nervous system
hemorrhage in three, and infarction in three. Respi-
ratory failure developed in 46 percent of patients with
neurologic complications; 92 percent of these pa-
tients underwent transfusion, and 23 percent died.
The mean hospital stay for these patients was 19.5
days, as compared with 9.4 days for the remainder of
the patients (P=0.008). Multivariable logistic-regres-
sion analysis of 11 variables that were significant on
univariate analysis showed that only the platelet count
remained an independent predictor of neurologic
complications during hospitalization (Table 3). Those
with relative thrombocytopenia (defined as a platelet
count of less than 200,000 per cubic millimeter) were
at the greatest risk for neurologic complications.
Complications occurred in 13 percent of all bron-
choscopic procedures (28 of 219). Half the compli-
cations consisted of a transient decline in oxygen sat-
uration. Laryngospasm occurred in 10 patients, and
pneumothorax developed in 2 patients, both of whom
had had the acute respiratory distress syndrome be-
fore the bronchoscopy. Eight patients underwent in-
tubation because of bronchoscopic complications. As
compared with the patients who underwent bron-
choscopy without incident, the patients who had
complications were more likely to present with dysp-
nea (61 percent vs. 36 percent, P=0.04) and higher
peak respiratory rates (mean, 47 vs. 41 per minute;
P=0.03).
Eighteen patients died. The primary causes of death
were respiratory failure from pulmonary emboli (bone
marrow, fat, or thrombotic) in six patients and bron-
chopneumonia in six. The causes of death in the re-
maining patients were pulmonary hemorrhage, cor
pulmonale, hypovolemic shock from splenic seques-
tration, overwhelming sepsis, intracranial hemorrhage,
and seizure. Overall, infection was a contributing
factor in 10 deaths. The organisms identified included
 
Streptococcus pneumoniae, Escherichia coli, Haemoph-
ilus influenzae, legionella, cytomegalovirus, Staphy-
lococcus aureus, and chlamydia.
Causes of the Acute Chest Syndrome
The causes of the acute chest syndrome are given
in Table 4. A specific cause (either pulmonary fat em-
bolism or an infectious agent) was identified in 256
(38 percent) episodes. After the exclusion of episodes
with incomplete data, a specific cause was identified
in 70 percent of episodes. Pulmonary infarction was
presumed to be the cause in 16 percent of episodes
in which there were complete data but no cause could
be identified.
Bronchoscopic or sputum samples were obtained
for analysis of fat embolisms in 72 percent of episodes.
The results for 15 percent of the bronchoscopic spec-
imens could not be interpreted. The majority of
these specimens contained large quantities of inflam-
matory cells that made it impossible to identify pul-
monary macrophages. A significantly larger percentage
of sputum samples were uninterpretable (42 percent,
P<0.001), in most cases because of contamination
with epithelial cells from the oropharynx or an in-
flammatory exudate.
Of the 27 different pathogens identified, C. pneu-
moniae was the most frequent, followed by M. pneu-
moniae and respiratory syncytial virus (Table 5). Par-
vovirus was isolated from a bronchial sample in 10
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*Only risk factors that were significant on multivariable regression analysis are included.
CI denotes confidence interval.
†Cox regression analysis was used, with data on patients who died censored at the time
of death.
‡Respiratory failure was defined as the need for mechanical ventilation.
§Odds ratios are given for risk factors that were significant on multivariable logistic regres-
sion. Only risk factors that were present at the time of diagnosis were included in the models.
TABLE 3. OVERALL PREDICTORS OF PROLONGED HOSPITALIZATION, 
RESPIRATORY FAILURE, AND NEUROLOGIC COMPLICATIONS 
AMONG PATIENTS WITH THE ACUTE CHEST SYNDROME.*
RISK FACTOR HAZARD RATIO (95% CI)† P VALUE
Prolonged hospitalization
Age
0 to 9.9 yr
10.0 to 19.9 yr
»20 yr
History of vaso-occlusive event
Pain in arms and legs on presentation





Radiographic evidence of effusion during 
hospitalization





Transfusion therapy during hospitalization































VENTILATION ODDS RATIO (95% CI)§ P VALUE
Respiratory failure‡
History of cardiac disease
No
Yes
































COMPLICATIONS ODDS RATIO (95% CI)§ P VALUE
Neurologic complications
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episodes. Severe reticulocytopenia was present in 5 of
these 10 episodes. In total, 249 pathogens were iden-
tified in 216 episodes. A single infectious pathogen
was identified in 172 episodes, multiple pathogens
were identified in 25 episodes, and fat embolism was
diagnosed together with an infectious agent in 19
episodes.
Comparison of Pulmonary Fat Embolism, Infection, 
and Infarction
We compared the characteristics of 53 patients
with fat embolism as a cause of a first episode of the
acute chest syndrome, 157 with infection as a cause,
and 82 with infarction as the presumed cause. More
patients in the fat-embolism group than in the infec-
tion group or the infarction group were 20 years of
age or older (30 percent vs. 22 percent and 13 per-
cent, P=0.003). The patients in the fat-embolism
group also had a lower mean oxygen saturation at
presentation (89 percent vs. 94 percent and 91 per-
cent, P=0.02) and were more likely to have upper-
lobe infiltrates during hospitalization (45 percent vs.
38 percent and 24 percent, P=0.04). The overall
rates of complications were similar in the three groups,
except for a higher incidence of vaso-occlusive events
in the fat-embolism group (74 percent vs. 54 per-
cent and 68 percent, P=0.02).
Comparison of Chlamydia and Mycoplasma Infections
We also compared the characteristics of the pa-
tients who were infected with the two most common
pathogens. As compared with patients with myco-
plasma infections, patients with chlamydia infections
were older (mean age, 17.8 vs. 11.3 years; P=0.02),
were less likely to be taking prophylactic antibiotics
(43 percent vs. 77 percent, P=0.006), and were more
likely to have a vaso-occlusive event during hospital-
ization (65 percent vs. 39 percent, P=0.04). At diag-
nosis, patients with chlamydia infections had higher
mean hemoglobin levels than did patients with myco-
plasma infections (8.0 vs. 7.0 g per deciliter, P=0.03).
In seven episodes M. hominis was the only agent
identified. The patients with M. hominis infections
were older than those with M. pneumoniae infections
(mean age, 19.6 vs. 10.2 years) but were similar in
other respects.
DISCUSSION
Although there is an increased awareness that the
acute chest syndrome is the leading cause of death
*Data on one episode were excluded because the patient’s birth date was not known.
†Nineteen of the episodes of pulmonary fat embolism were associated with infectious pathogens.
‡This category included episodes in which chlamydia alone was identified but not episodes involv-
ing mixed infections or pulmonary fat embolism.
§This category included episodes in which only Mycoplasma pneumoniae or Mycoplasma hominis
was identified, but not episodes involving mixed infections, Mycobacterium tuberculosis, or pulmonary
fat embolism.
¶This category included two cases of tuberculosis and one case of Mycobacterium avium complex
infection.
¿A pulmonary infarction was presumed to have occurred during episodes in which the results of
the analysis for pulmonary fat embolism, bacterial studies, viral-isolation studies, and serologic tests
were complete and were all negative.
**The cause of episodes for which some or all of the diagnostic data were incomplete and no eti-
ologic agent was identified was considered to be unknown.
TABLE 4. CAUSES OF THE ACUTE CHEST SYNDROME.*
CAUSE
ALL EPISODES 







no. of episodes (%)













































Unknown** 306 (45.7) 139 88 79
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in patients with sickle cell disease, the diagnosis is
often delayed, the optimal treatment is unknown,
and the cause is usually not determined. The longer
patients with sickle cell disease live, the higher the
frequency of recurrent pulmonary disease and result-
ant chronic lung disease.21 Despite the young age of
our patients, more than two thirds had a history of the
acute chest syndrome, and many had multiple epi-
sodes during the study.
The symptoms at presentation were age-depend-
ent; wheezing, cough, and fever were most common
among patients who were younger than 10 years of
age, whereas pain in the arms and legs and dyspnea
were more common among the adults.22 Almost half
the patients in whom the acute chest syndrome de-
veloped were admitted for other reasons, including
pain, and had radiographic and clinical symptoms
within three days after hospitalization. Clearly, pain
is a prodrome of the acute chest syndrome,22,23 and
a single physical examination or radiograph may not
be adequate for early diagnosis.
Laboratory values worsened after the diagnosis of
the syndrome despite aggressive intervention. As in
previous studies, we found that involvement of the
lower lobes predominated,9,22 radiographic abnormal-
ities progressed, and oxygenation and hemoglobin
levels declined. These findings indicate that serial
monitoring is necessary.
The average length of hospitalization was more
than 10 days and was longer than that reported in
previous studies.8,9 An older age, pain in the arms and
legs at presentation, fever, a low platelet count at di-
agnosis, extensive radiographic abnormalities, trans-
fusion therapy, and respiratory failure were associat-
ed with prolonged hospitalization. At the time of
diagnosis of the acute chest syndrome, patients who
went on to have respiratory failure were more likely
to have a history of cardiac disease, to have four or
more lobes affected, and to have platelet counts of
0 to 199,000 per cubic millimeter at base line. In the
general population, similar findings have been found
to be predictive of the severity of pneumonia, the
acute respiratory distress syndrome, and the acute
multiorgan-failure syndrome.24-26
There is a strong relation between the acute chest
syndrome and the occurrence of neurologic compli-
cations. Neurologic complications developed in 22
percent of the adults in our study. In nearly half these
patients, respiratory failure subsequently developed.
A recent history of a pulmonary event is the non-
neurologic risk factor that is the most highly predic-
tive of stroke.27 The mechanism most likely involves
sudden decreases in oxygenation in the vascular bed
of the central nervous system.27,28 Although our sta-
tistical model included only a small number of neuro-
logic events, the occurrence of relative thrombocyto-
penia has been associated with neurologic ischemic
insults and reflects the presence of hypoxia, tissue
damage, and platelet consumption.29,30 In addition,
fat embolism and infection with chlamydia or myco-
plasma may also play a direct part in brain injury.31,32
Our study evaluated interventions such as transfu-
sions, bronchodilators, antibiotics, and mechanical
ventilation. Almost three quarters of the patients re-
ceived transfusions because of a worsening clinical
course. Both exchange and simple transfusions im-
proved oxygenation, providing evidence to support
studies that demonstrate that limited transfusions al-
leviate organ dysfunction.33-35 The use of phenotypi-
cally matched units resulted in a 1 percent rate of
alloimmunization, which is lower than the rate of
7 percent that is associated with standard transfu-
sions,33 and pulmonary function improved with bron-
chodilator therapy. The 81 percent rate of recovery
after mechanical ventilation is better than the rate
among patients with the acute respiratory distress
syndrome.36 
The cause of the acute chest syndrome was estab-
lished in 38 percent of episodes, and pulmonary infarc-
*All infectious agents isolated during episodes of
the acute chest syndrome are included.
TABLE 5. INFECTIOUS PATHOGENS ISOLATED 







Respiratory syncytial virus 26
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tion was the presumed cause in another 16 percent.
In contrast to prior studies, in which specific causes
were seldom identified,2,22 infection and emboli were
common causes in our study. We examined broncho-
alveolar-lavage fluid because of previous reports of the
successful identification of bacterial pathogens and
pulmonary fat embolism in such specimens.10-12,37,38
Bronchoscopy produced higher-quality samples than
did the collection of sputum, although this proce-
dure was associated with a risk of complications. How-
ever, in 85 percent of samples, adequate material was
collected and the diagnostic yields were high.
We identified a large number of organisms that have
not usually been associated with the acute chest syn-
drome. Chlamydia was the most common isolate and
was associated with an increased rate of vaso-occlu-
sive events, although the rate of infection with this
organism was similar to that in the general popula-
tion.39,40 Mycoplasma and viral pneumonia, including
that caused by parvovirus, occurred in all age groups,
but predominated among young children.6 We also
found that M. hominis was responsible for seven ep-
isodes of the acute chest syndrome and legionella for
four. These organisms have not been considered caus-
es of the syndrome, but they should be.
As reported in previous studies,11,12 pulmonary fat
embolism was common in our study and the clinical
course of patients with this cause varied. Although the
catalyst of the syndrome may be pulmonary fat em-
bolism or infection, these events precipitate sickling,
regional hypoxia, and further ischemic damage.41-44
An environment ideal for sickle cell–related injury is
created by altering cellular adhesive molecules, dam-
aging the vascular endothelium, and stimulating cy-
tokines.11,23,41,43-45
In order to minimize lung injury in patients with
sickle cell disease, a comprehensive plan aimed at both
the catalyst and the host response is needed. Patients
should receive the influenza and pneumococcal vac-
cines, and they should be evaluated for respiratory
syncytial virus vaccine. Those admitted for painful
crises should be considered to be in the prodromal
phase of the acute chest syndrome; they require in-
centive spirometry and daily monitoring for pulmo-
nary disease.
Once the acute chest syndrome has been diag-
nosed, broad-spectrum antibiotics, including a mac-
rolide, are required. Airway hyperreactivity should be
assumed to be present, even if the patient is not
wheezing, and treatment with bronchodilators should
be initiated. Routine, early transfusions are indicated
for patients at high risk for complications, including
adults and those who have a history of cardiac dis-
ease and severe pain in the arms and legs at presenta-
tion. Those who present with severe anemia, thrombo-
cytopenia, or both and multilobar pneumonia should
receive a transfusion before respiratory distress devel-
ops. In most patients with anemia, treatment with leu-
kocyte-depleted, matched, simple transfusions is safe
and effective.
Bronchoscopy is recommended in patients with
no response to initial therapy because of the poten-
tial for organisms to be missed by analysis of sputum
samples. Preliminary reports suggest that corticoster-
oids and nitric oxide are beneficial in severe cases that
have not responded to other treatments.45,46 Given the
high rate of success with mechanical ventilation in our
study, aggressive ventilatory support, including ex-
tracorporeal membrane oxygenation, may be neces-
sary. After recovery, patients must be evaluated for
lung injury. Hydroxyurea, transfusion therapy, or bone
marrow transplantation may be indicated in patients
with recurrent events.
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APPENDIX
The following investigators also participated in the National Acute Chest
Syndrome Study Group: C. Daeschner (East Carolina University), P. Gron-
cy (Memorial Miller Children’s Hospital), R. Iyer (University of Mississip-
pi), T. Kinney (Duke University Medical Center), M. Koshy (University of
Illinois), W. Rackoff (Indiana University Medical Center), C. Pegelow
(University of Miami), H. Hume (St. Justine Hospital), J. Parke (Carolinas
Medical Center), L. McMahon (Boston Medical Center), L. Benjamin and
M. Bestak (Albert Einstein College of Medicine–Montefiore Hospital), F.
Little and Y. Ming-Yang (University of South Alabama), P. Waldron (Uni-
versity of Virginia), D. Wethers and G. Ramirez (St. Luke’s–Roosevelt
Hospital), N. Grossman (Columbus Children’s Hospital), S. Embury and
W. Mentzer (San Francisco General Hospital), M. Grossi (Children’s Hos-
pital of Buffalo), S. Claster (Summit Medical Center), L. Guarini (Inter-
faith Medical Center), M. Koehler (Children’s Hospital of Pittsburgh), J.
Eckman and T. Adamkiewicz (Emory University), E. Lowenthal (Univer-
sity of Alabama at Birmingham), P. Swerdlow (Medical College of Virgin-
ia), and C. Johnson (University of Southern California Medical Center).
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